Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + dexamethasone is an investigational combination therapy being evaluated by The University of Texas Medical Branch, Galveston, for the management of severe headaches in patients with spontaneous subarachnoid hemorrhage (SAH). The treatment involves the endovascular infusion of lidocaine, a local anesthetic, and dexamethasone, a corticosteroid, directly into the middle meningeal artery (MMA) via a microcatheter during angiography. This targeted delivery aims to provide pain relief by inducing vasoconstriction of the MMA and exerting anti-inflammatory effects on the cranial dura mater, which is primarily supplied by the MMA. This approach is currently being studied in a Phase 2 clinical trial to assess its efficacy and safety in reducing headache severity in the SAH population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + dexamethasone (University of Texas Medical Branch).